DVx Inc. Reports Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017; Provides Earnings Guidance for the Full Year Ending March 31, 2018; Provides Dividend Guidance for the Full Year Ending March 31, 2018
August 31, 2017
Share
DVx Inc. reported non-consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales of JPY 9,722 million, operating income of JPY 522 million, ordinary income of JPY 526 million, profit of JPY 371 million or earnings per share of JPY 32.99 compared to net sales of JPY 8,515 million, operating income of JPY 377 million, ordinary income of JPY 334 million, profit of JPY 234 million or earnings per share of JPY 20.76 per for the same period a year ago. Profit before income tax was JPY 524,560,000 against JPY 334,555,000 a year ago.
For the six months ending September 30, 2017, the company expects net sales of JPY 18,442 million, operating income of JPY 565 million, ordinary income of JPY 565 million, profit of JPY 379 million or earnings per share of JPY 33.61.
For the year ending March 31, 2018, the company expects net sales of JPY 38,377 million, operating income of JPY 1,171 million, ordinary income of JPY 1,171 million, profit of JPY 783 million or earnings per share of JPY 69.50.
For the full year ending March 31, 2018, the company expects to declare dividend of JPY 23.00 per share.
DVx Inc. is a Japan-based company mainly engaged in the sale of medical equipment for circulatory system diseases. The Company operates in two business segments. The Arrhythmia segment mainly sells cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), electrode catheters and ablation catheters. The Ischemia segment is engaged in the import and sale of automated contrast medium injectors under the name ACIST, excimer laser angioplasty systems, as well as sale of coronary artery stent products as agency business. The others business is engaged in the sale of neurosurgical products, general surgery related products, gastrointestinal related products, radiation protection supplies, among others.
DVx Inc. Reports Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017; Provides Earnings Guidance for the Full Year Ending March 31, 2018; Provides Dividend Guidance for the Full Year Ending March 31, 2018